Nilvadipine is effective for chronic schizophrenia in a double-blind placebo-controlled study

Journal of Clinical Psychopharmacology

Volumn 16, Issue 6, 1996, Pages 437-439

  Yamada, Kazuo ^a,b   Kanba, Shigenobu ^c   Ashikari, Iyoko ^a,b   Ohnishi, Kimio ^a   Yagi, Gohei ^a   Asai, Masahiro ^a  

^a KEIO UNIVERSITY   (Japan)

^b Department of Neuropsychiatry   (Japan)

^c UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

NILVADIPINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; EMOTION; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOSOCIAL WITHDRAWAL; SCHIZOPHRENIA;

ADULT; AGED; CALCIUM CHANNEL BLOCKERS; CHRONIC DISEASE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DYSKINESIA, DRUG-INDUCED; HUMANS; MALE; MIDDLE AGED; NIFEDIPINE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA;

EID: 0030459009     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199612000-00005     Document Type: Article

References (23)

1. Gould RJ, Murphy KMM, Reynolds IJ, Snyder SH. Antischizophrenic drugs of the diphenylbutylpiperidine type act as calcium channel antagonists. Proc Natl Acad Sci U S A 1983;80:5122-5.
2. Price WA, Giannini AJ, Loiselle RH. Verapamil in the treatment of schizophrenia [abstract]. J Clin Pharmacol 1985;25:461.
3. Price WA, Giannini AJ. Verapamil in acute psychosis [letter]. Psychosomatics 1986;27:797.
4. Price WA, Pascarzi GA. Use of verapamil to treat negative symptoms in schizophrenia [letter]. J Clin Psychopharmacol 1987;7: 357.
5. Price WA. Antipsychotic effects of verapamil in schizophrenia. Hillside J Clin Psychiatry 1987;9:225-30.
6. Tourjman SV, Bloom DM, Nair NPU. Verapamil in the treatment of chronic schizophrenia. Psychopharmacol Bull 1987;23:227-9.
7. Bartko G, Horvath S, Zador G, Frecska E. Effects of adjunctive verapamil administration in chronic schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 1991;15:343-9.
8. Kramer MS, DeMaria P, Morrow R, DiJohnson C, Sheves P. Nifedipine in neuroleptic-refractory schizophrenia. J Clin Psychopharmacol 1987;7:195-6.
9. Grebb JA, Shelton RC, Taylor EH, Bigelow LB. A negative, double-blind, placebo-controlled, clinical trial of verapamil in chronic schizophrenia. Biol Psychiatry 1986;21:691-1.
10. Schepelern S, Kfster A. Verapamil in treatment of severe schizophrenia. Acta Psychiatr Scand 1987;75:557-8.
11. Uhr SB, Jackson K, Berger PA, Csernansky JG. Effects of verapamil administration on negative symptoms of chronic schizophrenia. Psychiatry Res 1988;23:351-2.
12. Reiter S, Adler L, Angrist B, Peselow E, Rotrosen J. Effect of verapamil on tardive dyskinesia and psychosis in schizophrenic patients. J Clin Psychiatry 1989;50:26-7.
13. Stedman TJ, Whiteford HA, Eyles D, Welham JL, Pond SM. Effect of nifedipine on psychosis and tardive dyskinesia in schizophrenic patients. J Clin Psychopharmacol 1991;11:43-7.
14. Suddath RL, Straw GM, Freed WJ, Bigelow LB, Kirch DG, Wyatt RJ. A clinical trial of nifedipine in schizophrenia and tardive dyskinesia. Pharmacol Biochem Behav 1991;39:743-5.
15. Fujisawa YK. Medical supplies interview form of nilvadipine (Nivadil) [report]. Fujisawa-yakuhin-kougyou, Osaka, Japan 1992 (in Japanese).
16. Yamada K, Ashikari I, Onishi K, Kanba S, Yagi G, Asai M. Effectiveness of nilvadipine in two cases of chronic schizophrenia. Psychiatr Clin Neurosci 1995;49:237-8.
17. Davis J, Garvier DL. Neuroleptics: clinical use in psychiatry. In: Iversen LI, Iversen SD, Snyder SH, eds. Handbook of psychopharmacology, vol. 10. New York: Plenum Press, 1978:129-64.
18. Guy WG. BPRS Brief Psychiatric Rating Scale. ECDEU assessment manual for psychopharmacology, revised. Rockville, MD: U.S. Department of Health, Education and Welfare, 1976.
19. Middlemiss DN, Spedding M. A functional correlate for the dihydropyridine binding site in rat brain. Nature 1987;314:94-6.
20. Thayer SA, Welcome M, Chhabra A. Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and α-adrenergic receptors. Biochem Pharmacol 1985;34:175-80.
21. Pickar D, Wolkowitz OM, Doran AR, Labarca R, Roy A, Breier A, Narang PK. Clinical and biochemical effect of verapamil administration to schizophrenic patients. Arch Gen Psychiatry 1987;44: 113-8.
22. Otani K, Ishizaki T. Basic knowledge on drug interaction. Jpn J Psychiatric Treatment 1995;10:723-8 (in Japanese).
23. Duncan E, Adler L, Angrist B, Rotrosen J. Nifedipine in the treatment of tardive dyskinesia. J Clin Psychopharmacol 1990;10: 414-6.